Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.
In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.